Risk of Parkinson's disease dementia related to level I MDS PD-MCI

Jeroen Hoogland; Judith A Boel; Rob M A de Bie; Ben A Schmand; Ronald B Geskus; John C Dalrymple-Alford; Connie Marras; Charles H Adler; Daniel Weintraub; Carmen Junque; Kenn F Pedersen; Brit Mollenhauer; Jennifer G Goldman; Alexander I Tröster; David J Burn; Irene Litvan; Gert J Geurtsen; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”

doi:10.1002/mds.27617

Risk of Parkinson's disease dementia related to level I MDS PD-MCI

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

Authors

Jeroen Hoogland¹, Judith A Boel^{1

2}, Rob M A de Bie¹, Ben A Schmand^{2

3}, Ronald B Geskus^{4

5

6}, John C Dalrymple-Alford⁷, Connie Marras⁸, Charles H Adler⁹, Daniel Weintraub¹⁰, Carmen Junque¹¹, Kenn F Pedersen¹², Brit Mollenhauer¹³, Jennifer G Goldman¹⁴, Alexander I Tröster¹⁵, David J Burn¹⁶, Irene Litvan¹⁷, Gert J Geurtsen³; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”

Affiliations

¹ Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
³ Department of Medical Psychology, Academic Medical Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁴ Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
⁶ Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.
⁷ New Zealand Brain Research Institute, Brain Research New Zealand - Rangahau Roro Aotearoa, Christchurch, New Zealand.
⁸ Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Ontario, Canada.
⁹ Arizona Parkinson's Disease Consortium, Mayo Clinic Arizona, Scottsdale, Arizona, USA, and Banner Sun Health Research Institute, Sun City, Arizona, USA.
¹⁰ Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
¹¹ Department of Medicine, Faculty of Medicine, IDIBAPS, University of Barcelona, Barcelona, Spain.
¹² The Norwegian Centre for Movement Disorders, Department of Neurology, and Memory Clinic, Stavanger University Hospital, Stavanger, Norway.
¹³ Department of Neurosurgery and Institute of Neuropathology, Paracelsus-Elena-Klinik, Kassel, Germany, and University Medical Center Goettingen, Goettingen, Germany.
¹⁴ Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, Illinois, USA.
¹⁵ Department of Clinical Neuropsychology and Center for Neuromodulation, Barrow Neurological Institute, Phoenix, Arizona, USA.
¹⁶ Institute of Neuroscience, Newcastle University, Upon Tyne, Newcastle, UK.
¹⁷ Department of Neurosciences University of California San Diego, Parkinson and Other Movement Disorder Center, San Diego, California, USA.

PMID: 30653248
DOI: 10.1002/mds.27617

Abstract

Background: The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.

Methods: We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.

Results: Level I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.

Conclusions: Level I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; dementia; mild cognitive impairment; neuropsychological tests; survival analysis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Age Factors
Aged
Cognitive Dysfunction / etiology*
Dementia / etiology*
Female
Humans
Male
Middle Aged
Neuropsychological Tests
Parkinson Disease / complications*
Risk Factors
Sex Factors

Abstract

Publication types

MeSH terms

Grants and funding